Statement Of Cash Flows [Abstract]

Xspray Pharma - Filing #679275

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations before changes in working capital
171 694 SEK
106 604 SEK
Adjustments for decrease (increase) in trade and other receivables
4 109 SEK
2 942 SEK
Adjustments for increase (decrease) in trade and other payables
7 757 SEK
633,000 SEK
Adjustments for gain (loss) on disposals, property, plant and equipment
5,000 SEK
- SEK
Cash flows from (used in) investing activities [abstract]
Payments for development project expenditure
49 855 SEK
103 820 SEK
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
26 201 SEK
4 876 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.